Gonadotropin Deficiency: Causes, Signs, and Management

Gonadotropin deficiency means the body fails to produce enough of the hormones, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), that drive sexual development, fertility, and sex-hormone production. The condition can be present from birth or develop later due to tumors, medications, extreme stress, or other insults to the brain’s hormonal control center. Because the downstream effects touch puberty, bone strength, mood, and reproductive capacity, a delayed or missed diagnosis carries consequences that extend well beyond fertility.

How the Signaling Chain Works

The hypothalamus releases gonadotropin-releasing hormone (GnRH) in rhythmic pulses. The pattern of those pulses matters: it regulates not just how much LH and FSH the pituitary gland secretes, but also how the pituitary assembles and stores those hormones in the first place.¹ LH and FSH then travel through the bloodstream to the ovaries or testes, where they stimulate sex-hormone production and the maturation of eggs or sperm. When GnRH pulses slow down, become erratic, or stop altogether, the pituitary loses its cue, gonadotropin levels fall, and the gonads are left without instructions.

This chain of command is why clinicians distinguish between two broad categories. In primary hypogonadism the gonads themselves are the problem: they fail despite normal or even elevated LH and FSH levels, because the pituitary is shouting louder to compensate. In gonadotropin deficiency (also called secondary or central hypogonadism), LH and FSH are inappropriately low or normal while sex hormones are also low, pointing to a fault in the hypothalamus or pituitary rather than the gonads.

Congenital Causes

Some people are born with a hypothalamus or pituitary that never learned to produce GnRH pulses properly. The best-known genetic form is Kallmann syndrome, which pairs gonadotropin deficiency with a reduced or absent sense of smell. About 60% of people diagnosed with congenital hypogonadotropic hypogonadism (CHH) have some degree of smell loss, qualifying them for the Kallmann label.² The remaining 40% have normal olfaction and are classified as having normosmic CHH.

The genetics are remarkably tangled. Research over the past three decades has tied variants in at least 44 genes to CHH, yet even that long list accounts for only about half of all cases.³ Among the earliest discoveries were mutations in the gene now called ANOS1 (formerly KAL1), which causes an X-linked form of Kallmann syndrome, and mutations in FGFR1, which can follow autosomal dominant inheritance with incomplete penetrance.⁴ Mutations in PROKR2 and PROK2, identified more recently, can appear in heterozygous, homozygous, or compound heterozygous states and may contribute to both single-gene and multi-gene forms of the disease.⁴

What makes genetic counseling tricky is that the same family can harbor different mutations with strikingly different outcomes. In one reported family, a father with FGFR1 mutation had normosmic CHH, while his son carried the same FGFR1 mutation plus an additional rare PROKR2 variant and presented with classic Kallmann syndrome including anosmia.⁵ This kind of oligogenic inheritance, where the severity of the condition depends on the combined burden of variants across multiple genes, makes the genetic picture considerably harder to predict than a simple dominant-or-recessive model would suggest.

Acquired Causes

Gonadotropin deficiency that develops after birth has a broader and more varied set of triggers. Some are reversible; others are not.

Tumors and surgery: Growths in or near the pituitary gland, such as craniopharyngiomas, can physically compress or destroy the tissue responsible for GnRH signaling. Surgical removal and radiation therapy carry their own risk of damaging the hypothalamic-pituitary unit, sometimes trading a tumor problem for a lifelong hormone-replacement need.⁶
Stress, undereating, and overexercise: In women, the combination of psychological stress, insufficient calorie intake, and intense physical training can shut down GnRH pulsatility, causing periods to stop. This is known as functional hypothalamic amenorrhea.⁷ It is technically a form of acquired gonadotropin deficiency and is reversible once the underlying stressors are addressed.
High prolactin levels: Elevated prolactin, whether from a pituitary prolactinoma or certain medications, suppresses a group of hypothalamic neurons that use a signaling molecule called kisspeptin. The result is reduced GnRH release, lower LH and FSH, and ultimately amenorrhea and infertility.⁸
Opioid medications: Long-term opioid use directly inhibits GnRH pulsatility through receptors in the hypothalamus. Opioids also act on the pituitary itself to suppress gonadotropin release, creating a double hit that lowers testosterone or estrogen.⁹

Opioid-induced hypogonadism deserves particular attention because chronic pain management with opioids is common, and the hormonal consequences are under-recognized. Many people on long-term opioids develop fatigue, low libido, and depressed mood that get attributed to the underlying pain condition rather than to hormone disruption.

Signs and Symptoms

What gonadotropin deficiency looks like depends heavily on when it starts. If the condition is present from birth, boys may be born with undescended testes or a micropenis, though these signs are frequently overlooked in infancy.¹⁰ The more dramatic presentation comes at the expected age of puberty, when development simply fails to begin: no growth spurt, no deepening of the voice, no testicular enlargement. Girls with congenital forms typically present with absent or incomplete breast development and failure to start menstruating.

In adults who acquire gonadotropin deficiency later in life, the signs overlap with what most people associate with low testosterone or low estrogen. In men these include reduced sex drive, erectile difficulties, loss of muscle mass, increased body fat, fatigue, depressed mood, and weakened bones.¹¹ Women may experience irregular or absent periods, vaginal dryness, hot flashes, and low libido. In both sexes, prolonged deficiency contributes to osteoporosis and metabolic disturbances.¹²

Partial forms of congenital gonadotropin deficiency add a layer of diagnostic difficulty. Some adolescents have enough residual GnRH activity to start puberty but not enough to complete it, resulting in stalled development and subtle signs of low sex hormones that can be mistaken for simple “late blooming.”¹³

How the Diagnosis Is Made

Blood work is the starting point. The hallmark of gonadotropin deficiency is finding low testosterone or estradiol alongside LH and FSH levels that are low or inappropriately normal. In primary hypogonadism, by contrast, the gonadotropins would be elevated because the pituitary is trying to compensate for failing gonads. In practice, distinguishing gonadotropin deficiency from constitutional delay of puberty in a teenager can be one of the harder calls in pediatric endocrinology, because both present with low hormones and late development.

Stimulation tests can help. In girls, a stimulated FSH level above a certain threshold reliably separates those who will go through puberty on their own from those with true hypogonadotropic hypogonadism.¹⁴ Boys are more commonly assessed with GnRH analog stimulation protocols, though no single test has perfect accuracy.

Smell testing plays a surprisingly useful role. Because Kallmann syndrome couples gonadotropin deficiency with anosmia, a formal olfactory assessment can help classify the condition and guide genetic testing. Standardized smell tests achieve about 86% sensitivity and 97% specificity for distinguishing Kallmann syndrome from the normosmic form, and MRI evaluation of the olfactory bulbs has comparable diagnostic accuracy.¹⁵ On MRI, patients with Kallmann syndrome typically show absent or severely underdeveloped olfactory bulbs, whereas those with normosmic CHH have normal or near-normal bulb structure.¹⁶ A strong correlation exists between olfactory bulb volume on MRI and objective smell-test scores, which means the two assessments tend to agree.¹⁷

MRI of the brain and pituitary is also essential for ruling out structural causes like tumors, empty sella syndrome, or infiltrative diseases. Genetic testing has become more accessible with next-generation sequencing panels, though results change management mainly by informing genetic counseling and predicting certain subtypes rather than altering treatment itself.¹⁸

Treatment Strategies

The choice of treatment hinges on the immediate goal. For someone who needs pubertal development or sex-hormone replacement but is not currently trying to conceive, testosterone (in males) or estrogen-progesterone therapy (in females) is the standard approach. These hormones restore the missing downstream effects: secondary sexual characteristics, bone density, muscle mass, and psychological well-being. However, exogenous testosterone suppresses the pituitary’s own LH and FSH production even further, which means sperm production shuts down almost entirely while on it.

When fertility is the goal, the treatment strategy changes. Congenital hypogonadotropic hypogonadism is one of the few forms of male infertility that responds well to gonadotropin therapy. Injections of human chorionic gonadotropin (which mimics LH) and FSH can stimulate the testes to produce both testosterone and sperm, effectively bypassing the hypothalamic-pituitary defect.¹⁹ In women, similar gonadotropin protocols are used for ovulation induction. Alternatively, pulsatile GnRH delivered through a portable pump can restore the natural signaling rhythm, prompting the pituitary to resume its own LH and FSH production.

In acquired cases, treating the underlying cause can sometimes resolve the deficiency entirely. Correcting hyperprolactinemia with dopamine agonists, reducing opioid doses, or reversing the caloric deficit behind functional hypothalamic amenorrhea can all restore normal gonadotropin secretion without lifelong replacement.

Spontaneous Reversal

One of the more unexpected findings in this field is that congenital hypogonadotropic hypogonadism is not always permanent. Some men who have been on testosterone replacement for years will, after a trial off treatment, turn out to have recovered normal hormonal function on their own. A study that tracked men with the condition found sustained spontaneous reversal in 15 individuals after treatment was interrupted, and among those, four had the anosmia associated with Kallmann syndrome.²⁰

Larger analyses have begun to identify who is more likely to reverse. Patients who experienced partial puberty before diagnosis, who had larger testicular volume at baseline, and who carried fewer rare genetic variants were more likely to recover function. Patients without reversal were more likely to have anosmia, cryptorchidism, complete absence of puberty, and oligogenic mutations across multiple genes.²¹ Interestingly, among patients who reversed, none carried pathogenic variants in the ANOS1 gene, while GNRHR mutations were over-represented in the reversal group compared to those who did not reverse.²¹

The clinical takeaway is that periodic re-evaluation matters. Clinicians are increasingly encouraged to try brief, supervised treatment interruptions in stable patients to check whether endogenous function has returned. Missing a reversal means continuing unnecessary hormone therapy and potentially suppressing fertility that could otherwise occur naturally.

Psychological and Social Burden

The physical effects of gonadotropin deficiency tend to get the most medical attention, but the psychological fallout can be equally damaging. Adolescents and young adults with congenital forms frequently report feelings of isolation, shame, and being “left behind” as their peers go through puberty.²² Focus-group research with CHH patients identified four persistent themes: body-image concerns, low self-esteem, anxiety and depression, and a sense of developmental mismatch with peers.²³

Diagnostic delay compounds the problem. Because Kallmann syndrome can technically be suspected in infancy when cryptorchidism or micropenis is noted, waiting until a teenager fails to enter puberty means years of avoidable distress.¹⁰ The rarity of the condition works against early detection: general pediatricians may see only one or two cases in a career, and the “wait and see” approach to late puberty, while appropriate for most teenagers, can cost children with true CHH several formative years. Patients and advocacy groups have pushed for earlier screening protocols, particularly when neonatal red flags are present, and for integrating psychological support into routine endocrine follow-up rather than treating it as an afterthought.

Kisspeptin and the Research Frontier

Much of the recent excitement in the field revolves around kisspeptin, the signaling molecule that sits upstream of GnRH neurons and acts as a master switch for reproductive function. When prolactin suppresses kisspeptin neurons, GnRH drops and gonadotropins follow. Researchers have shown that administering kisspeptin-10 directly to women with hyperprolactinemic amenorrhea can trigger rapid, substantial rises in LH and FSH, suggesting that the GnRH neurons themselves remain functional and just need the right nudge.²⁴

The therapeutic potential here goes beyond hyperprolactinemia. In theory, drugs that boost kisspeptin or neurokinin B signaling (both part of the same neuronal circuit) could treat various forms of gonadotropin deficiency by restarting the GnRH pulse generator rather than replacing hormones from outside.²⁵ Animal research has clarified where the limits lie: in models completely lacking the kisspeptin gene, a kisspeptin receptor agonist failed to stimulate LH secretion, confirming that the pathway requires at least some intact kisspeptin machinery to function.²⁶ For patients whose deficit is partial, though, kisspeptin-based therapies could eventually offer a more physiological alternative to gonadotropin injections, one that restores natural hormonal rhythms rather than imposing artificial ones. Clinical trials in humans are still in the early phases, but the proof of concept is strong enough that several research groups are actively developing longer-acting kisspeptin analogs for potential clinical use.

Long-Term Skeletal and Metabolic Risks

Sex hormones are not just about reproduction. Testosterone and estrogen both play direct roles in maintaining bone density, regulating fat distribution, and protecting cardiovascular health. When gonadotropin deficiency leaves sex hormones chronically low, bones lose mineral content faster than they gain it, raising the risk of osteoporosis and fractures at ages when they would otherwise be rare.¹² Young men with untreated CHH can present with bone density scores typically seen in postmenopausal women, which is jarring for both patient and clinician.

The metabolic picture adds further urgency. Prolonged low testosterone in men correlates with increased visceral fat, insulin resistance, and unfavorable cholesterol profiles. These changes are not merely cosmetic; they shift cardiovascular risk. Hormone replacement generally improves bone density, body composition, and metabolic markers, but the degree of recovery depends on how long the deficiency went untreated and how much skeletal growth was missed during the critical pubertal window. For individuals whose condition was caught after peak bone-mass accrual should have occurred, full catch-up may not be possible even with optimal therapy. This is one more reason early diagnosis carries weight that extends far beyond the immediate concern of puberty timing.

1
PubMed Central. GnRH pulses–the regulators of human reproduction
2
PubMed Central. The genetic and molecular basis of idiopathic hypogonadotropic hypogonadism
3
PubMed. Genetics of hypogonadotropic Hypogonadism-Human and mouse genes, inheritance, oligogenicity, and genetic counseling
4
European Journal of Human Genetics. Kallmann syndrome
5
PubMed Central. Additional mutation in PROKR2 and phenotypic differences in a Kallmann syndrome/normosmic congenital hypogonadotropic hypogonadism family carrying FGFR1 missense mutation
6
Frontiers in Endocrinology. Characteristics and factors influencing hypothalamic pituitary dysfunction in patients with craniopharyngioma
7
PubMed Central. Functional Hypothalamic Amenorrhea: Recognition and Management of a Challenging Diagnosis
8
The Journal of Clinical Investigation. Hyperprolactinemia and infertility: new insights
9
PubMed Central. Long-term Opioids Linked to Hypogonadism and the Role of Testosterone Supplementation Therapy
10
European Journal of Endocrinology. NE19 Kallmann syndrome missed in infancy: diagnostic delay despite early clinical red flags
11
PubMed Central. A practical guide to male hypogonadism in the primary care setting
12
PubMed Central. The complications of male hypogonadism: is it just a matter of low testosterone?
13
PLOS ONE. GnRH receptor gene mutations in adolescents and young adults presenting with signs of partial gonadotropin deficiency
14
PubMed. Accuracy of Endocrine Tests for Detecting Hypogonadotropic Hypogonadism in Girls
15
Frontiers in Endocrinology. The diagnostic value of the olfactory evaluation for congenital hypogonadotropic hypogonadism
16
PubMed. Kallman syndrome versus idiopathic hypogonadotropic hypogonadism at MR imaging
17
PubMed. An objective olfactory evaluation and its correlation with magnetic resonance imaging findings in Asian Indian patients with idiopathic hypogonadotropic hypogonadism
18
PubMed Central. Advances in Genetic Diagnosis of Kallmann Syndrome and Genetic Interruption
19
PubMed Central. Treatment of congenital hypogonadotropic hypogonadism in male patients
20
PubMed. Reversal of idiopathic hypogonadotropic hypogonadism
21
The Lancet Diabetes & Endocrinology. Congenital hypogonadotropic hypogonadism reversal and classes of reversal
22
PubMed Central. Psychological Aspects of Congenital Hypogonadotropic Hypogonadism
23
PubMed Central. Identifying the unmet health needs of patients with congenital hypogonadotropic hypogonadism using a web-based needs assessment: implications for online interventions and peer-to-peer support
24
Journal of the Endocrine Society. Hypothalamic-Pituitary-Ovarian Axis Reactivation by Kisspeptin-10 in Hyperprolactinemic Women With Chronic Amenorrhea
25
Human Reproduction Update. The kisspeptin-GnRH pathway in human reproductive health and disease
26
Biology of Reproduction. Gonadotropin secretion and ovarian response of KISS1 knockout gilts treated with hormone analogs activating the hypothalamic–pituitary-gonadal axis